Targeting Regnase-1 programs long-lived effector T cells for cancer therapy

Adoptive cell therapy represents a new paradigm in cancer immunotherapy but can be limited by poor persistence and function of transferred T cells(1). Here, through an in vivo pooled CRISPR-Cas9 mutagenesis screening, we demonstrate that CD8(+) T cells are reprogrammed to long-lived effector cells w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jun, Long, Lingyun, Zheng, Wenting, Dhungana, Yogesh, Lim, Seon Ah, Guy, Cliff, Wang, Yanyan, Wang, Yong-Dong, Qian, Chenxi, Xu, Beisi, Anil, KC, Saravia, Jordy, Huang, Hongling, Yu, Jiyang, Doench, John G., Geiger, Terrence L., Chi, Hongbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937596/
https://www.ncbi.nlm.nih.gov/pubmed/31827283
http://dx.doi.org/10.1038/s41586-019-1821-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937596/
https://www.ncbi.nlm.nih.gov/pubmed/31827283
http://dx.doi.org/10.1038/s41586-019-1821-z

Ejemplares similares